epratuzumab epratuzumab epratuzumab (planned trade name lymphocide) is a humanized monoclonal antibody. potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (sle). epratuzumabmonoclonal antibodytypewhole antibodysourcehumanized (from mouse)targetcd22clinical datatrade nameslymphocideatc codenonelegal statuslegal status investigational identifierscas number205923-57-5 npubchem sid47206001iuphar/bps8088drugbankdb04958 nchemspidernoneunii3062p60mh9keggd04036 y ny (what is this?) (verify) clinical trials a clinical trial for relapsed adult acute lymphoblastic leukemia (all) has reported initial results. results have been published for a phase ii trial in untreated follicular lymphoma. early results from a phase ii trial for diffuse large b-cell lymphoma (dlbcl) were encouraging. the manufacturers in august 2009 announced success in early trials against sle, and started two phase iii clinical trials. july 2015 : both phase iii trials (embody1/2) for sle failed to meet their primary endpoint. mechanism of action epratuzumab binds to the glycoprotein cd22 of mature and malignant b-cells. elevated cd22 and other b-cell receptor (bcr) proteins are associated with sle. "epratuzumab's mechanism of action transfers these bcr proteins to helper cells called effector cells which reduces b-cell destruction and epratuzumab's impact on the body's immune system" via a process called trogocytosis. other sle therapies destroy b-cells which compromises the immune system.